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Cancer is one of the leading
causes of death among Americans. It is
estimated that approximately one-third
of all Americans will be diagnosed with
some form of cancer in the next 20 years
(World Health Organization [WHO]).
There are numerous types of cancer but
the most common types are lung cancer,
breast cancer (women) and prostate
cancer (men), which also happens to
have the highest mortality rate (WHO).
Because these three forms of cancer are
very dangerous, it is important to learn
more about cancer to find a cure.
Unlike normal cells, cancer cells have
the enzyme telomerase which prevents
telomeres from degenerating so that
the cell continues to divide (El-Daly et
al., 2005). One of the drugs often used
to treat cancer patients are telomerase
inhibitors, but cancer cells are becoming
increasingly resistant to the drug. BIBR
1532 is a known telomerase inhibitor
and is currently in clinical trials for
treating cancers. For a drug to be a good
telomerase inhibitor like BIBR 1532, it
must have a carboxylic acid structure
bonded to an aromatic ring and a
conjugated amine.
There were 18 drugs synthesized
in the Department of Chemistry in
the labs of Dr. Robert Smart and Dr.
William Schroeder based on the structure
of BIBR 1532. These drugs have been
tested in our lab to see whether they
show any antiproliferative effect. Out of
the 18 drugs screened, about 4-5 drugs
(4-43A, WS 1248, WS 76, WS 648, WS
1214) have shown an antiproliferative
effect when tested against metastatic
prostate cell lines that have known high
telomerase activity. The drugs identified
with anti-telomerase activity will be tested
first at different concentrations to find
the optimal concentration that inhibits
proliferative activity. After the optimal
concentration is identified, all the cells
will be treated at this concentration
and the treated cells will be frozen until
further use for telomerase assay. Those
drugs with antiproliferative effects will
be further tested to see if they are good
telomerase inhibitors by subjecting them

to telomerase assays. The cell will be
lysed and analyzed using TRAP assay
to test whether the telomerase present in
the cancer cell is inhibited by the drug or
through a different mechanism.
This research is important because
if the drugs tested are proven to be good
telomerase inhibitors then they could be
used to effectively treat prostate, breast
and lung cancer, which are known to have
high telomerase activity and are known to
be fatal.
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